Amgen Inc. (NASDAQ:AMGN) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday. They presently have a $167.77 target price on the medical research company’s stock. Vetr‘s price objective would indicate a potential upside of 12.57% from the company’s current price.

AMGN has been the subject of a number of other reports. BMO Capital Markets restated an “outperform” rating and issued a $190.00 price objective on shares of Amgen in a research report on Thursday, September 22nd. Jefferies Group restated a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Tuesday, August 23rd. Credit Suisse Group AG set a $206.00 price objective on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. Leerink Swann restated a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Finally, Argus restated a “buy” rating and issued a $195.00 price objective (up from $185.00) on shares of Amgen in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and an average price target of $182.04.

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Shares of Amgen (NASDAQ:AMGN) opened at 149.04 on Thursday. The firm’s 50-day moving average is $157.92 and its 200-day moving average is $161.19. The company has a market capitalization of $110.87 billion, a price-to-earnings ratio of 14.92 and a beta of 1.15. Amgen has a 12-month low of $133.64 and a 12-month high of $176.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.23. The firm earned $5.81 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $2.72 earnings per share. On average, equities analysts predict that Amgen will post $11.56 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be given a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Monday, November 14th. Amgen’s dividend payout ratio is presently 39.92%.

Institutional investors have recently bought and sold shares of the company. New York Life Trust Co. raised its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock valued at $104,000 after buying an additional 221 shares in the last quarter. Penserra Capital Management LLC raised its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock valued at $114,000 after buying an additional 342 shares in the last quarter. Oakworth Capital Inc. raised its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares in the last quarter. Valley National Advisers Inc. raised its position in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock valued at $109,000 after buying an additional 33 shares in the last quarter. Finally, Glassman Wealth Services raised its position in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock valued at $110,000 after buying an additional 600 shares in the last quarter. 79.07% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.